> ## Content Index > Fetch the complete content index at: https://www.whiteroseintelligence.com/llms.txt > Use this file to discover other available public pages before exploring further. # 2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions - URL: https://www.whiteroseintelligence.com/2nd-global-consultation-on-sars-cov-2-variants-of-concern-and-the-impact-on-public-health-interventions/ - Published: 1999-01-02T08:11:00.000Z - Updated: 2024-12-31T07:26:06.000Z - Author: Liam Sturgess - Tags: Profiles, #docs The **2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions** was a meeting held by the [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) (WHO) on June 10, 2021.[\[1\]](#fn1) The event followed the [1st Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions](https://www.whiteroseintelligence.com/1st-Global-Consultation-on-SARS-CoV-2-Variants-of-Concern-and-the-Impact-on-Public-Health-Interventions) on March 29, 2021.[\[2\]](#fn2) ## Participants | Name | Affiliation | Topic | | ------------- | -------------------------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------ | | Michael Ryan | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Opening remarks | | Sylvie Briand | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Updates on the WHO global risk monitoring and assessment framework for SARS-CoV-2 variants | **Session 1: Focus on SARS-CoV-2 Variants** | Name | Affiliation | Topic | | ------------------ | -------------------------------------------------------------------------------------------- | --------------------------------------------------------- | | Maria Van Kerkhove | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Moderator | | Lorenzo Subissi | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Update on VOI/VOC designation process and naming system | | Brett Archer | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Global epidemiological situation with SARS-CoV-2 variants | | Wendy Barclay | Imperial College London | Risk assessing SARS-CoV-2 variants | **Session 2: Evidence Framework for Variants and COVID-19 Vaccines** | Name | Affiliation | Topic | | ------------------- | ------------------------------------------------------------------------------------------------------------------------------------ | ---------------------------------------------------------------------------------------------------------------------- | | Kanta Subbarao | Peter Doherty Institute for Infection and Immunity | Moderator | | Philip Krause | [Food and Drug Administration](https://www.whiteroseintelligence.com/Food-and-Drug-Administration) (FDA) | Decision-making process and methods to decide if a modified vaccine or a new vaccine is needed | | Isabelle Boutron | Paris Descartes University | Review and critical appraisal of randomized evidence on vaccines and variants | | Julian Higgins | University of Bristol | Review and critical appraisal of non-randomized evidence on vaccines and variants | | Luigi Aurisicchio | Takis Biotech, Rottapharm Biotech | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Prakash Bhuyan | [AstraZeneca](https://www.whiteroseintelligence.com/AstraZeneca) | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | J. Robert Coleman | Codagenix | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Philip Dormitzer | [Pfizer](https://www.whiteroseintelligence.com/Pfizer) | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Randall Hyer | [Moderna](https://www.whiteroseintelligence.com/Moderna) | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Mathieu Le Gars | [Janssen](https://www.whiteroseintelligence.com/Janssen) | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Allen Lien | Medigen Vaccine Biologics Corporation | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Krishna Mohan | Bharat Biotech | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Piyush Patel | [Providence Therapeutics](https://www.whiteroseintelligence.com/Providence-Therapeutics) | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Trina Racine | Vaccine and Infectious Disease Organization (VIDO) | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | Christine Roberts | GeneOne Life Science | Developers’ corner – current data and plans for evaluation of the effect of variants on vaccine efficacy/effectiveness | | John Peter Figueroa | University of the West Indies | Preliminary considerations of other epidemiological data to inform decisions | | Mary Ramsay | Public Health England | Preliminary considerations of other epidemiological data to inform decisions | | Helen Rees | University of the Witwatersrand | Preliminary considerations of other epidemiological data to inform decisions | | David Wentworth | [Centers for Disease Control and Prevention](https://www.whiteroseintelligence.com/Centers-for-Disease-Control-and-Prevention) (CDC) | Preliminary considerations of other epidemiological data to inform decisions | **Session 3: Impact on Public Health Decision-Making** | Name | Affiliation | Topic | | -------------------- | ----------------------------------------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------------------------------- | | Marco Cavaleri | [European Medicines Agency](https://www.whiteroseintelligence.com/European-Medicines-Agency) (EMA) | Moderator | | Chang-Joon Bae | Ministry of Food and Drug Safety | Perspectives of regulators and developers for variants and [COVID-19 vaccines](https://www.whiteroseintelligence.com/COVID-19-vaccine) | | Adam Hacker | [Coalition for Epidemic Preparedness Innovations](https://www.whiteroseintelligence.com/Coalition-for-Epidemic-Preparedness-Innovations) (CEPI) | Perspectives of regulators and developers for variants and COVID-19 vaccines | | Philip Krause | [Food and Drug Administration](https://www.whiteroseintelligence.com/Food-and-Drug-Administration) (FDA) | Perspectives of regulators and developers for variants and COVID-19 vaccines | | Nyka Alexander | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Moderator | | Christine Carrington | University of the West Indies | Impact of variants on public health decision-making: Global perspective; Country level perspectives | | Nazeem Muhajarine | University of Saskatchewan | Impact of variants on public health decision-making: Global perspective; Country level perspectives | | Hanna Nohynek | Strategic Advisory Group of Experts on Immunization (SAGE) | Impact of variants on public health decision-making: Global perspective; Country level perspectives | | Jaouad Mahjour | [World Health Organization](https://www.whiteroseintelligence.com/World-Health-Organization) | Concluding remarks | ## Contributors In the official report from the event, the WHO acknowledges contributions from the following individuals: - Nyka Alexander - Claudia Alfonso - Maya Allan - Brett Archer - Melanie Archer - Adedoyin Awofisayo-Okuyelu - April Baller - Celine Barnadas - Isabel Bergeri - Silvia Bertagnolio - Sylvie Briand - Lisa Carter - Christopher Chadwick - Sebastian Cognat - Natasha Crowcroft - Janet Diaz - Rogerio Gaspar - Enwere Godwin - Rebecca Grant - Blanche Greene-Cramer - Thomas Grein - Assil Farah - Daniel Feikin - Julia Fitzner - Esther Hamblion - Ana Maria Henao-Restrepo - Siddhivinayak Shriram Hirve - Joachim Hombach - Anne Huvos - Anna-Lea Kahn - Zyleen Alnashir Kassamali - Shagun Khare - Frank Konings - Krutika Kuppalli - Marta Lado Castro-Rial - Dianliang Lei - Olivier Le Polain - Ann Lindstrand - Jaouad Mahjour - Raquel Medialdea Carrera - Ryoko Miyazaki-Krause - Ann Moen - Oliver Morgan - Deusdedit Mubangizi - Mick Mulders - Katherine O’Brien - Boris Pavlin - Dmitriy Pereyaslov - Mark Perkins - Jacobus Preller - Pryanka Relan - Michael Ryan - Jilian Sacks - Gina Samaan - Archana Seahwag - Fatima Serhan - Juan Soriano Ortiz - Ute Stroher - Lorenzo Subissi - Soumya Swaminatha - Jordan Tappero - Katelijn Vandemaele - Maria Van Kerkhove - Marie-Ange Wambo - Annelies Wilder-Smith - David Wood - Halima Noor Yarow - Wenqing Zhang ## External links - [Campfire Wiki](https://www.campfire.wiki/doku.php?id=2nd%5Fglobal%5Fconsultation%5Fon%5Fsars-cov-2%5Fvariants%5Fof%5Fconcern%5Fand%5Ftheir%5Fimpact%5Fon%5Fpublic%5Fhealth%5Finterventions) - [Meeting Report](https://web.archive.org/web/20230410003203/https://www.who.int/docs/default-source/coronaviruse/report-sars-global-consultation%5F10june2021.pdf) --- 1. *2nd Global Consultation on SARS-CoV-2 Variants of Concern and the Impact on Public Health Interventions.* (2021). World Health Organization. [↩︎](#fnref1) 2. *Global Consultation on a Decision Framework for Assessing the Impact of SARS-CoV-2 Variants of Concern on Public Health Interventions.* (2021, March 29). World Health Organization. [↩︎](#fnref2)